KR20200126262A - A composition for ameliorating atopic dermatitis through specific inhibition of Staphylococcus aureus comprising alpha-vinipherin - Google Patents

A composition for ameliorating atopic dermatitis through specific inhibition of Staphylococcus aureus comprising alpha-vinipherin Download PDF

Info

Publication number
KR20200126262A
KR20200126262A KR1020190050033A KR20190050033A KR20200126262A KR 20200126262 A KR20200126262 A KR 20200126262A KR 1020190050033 A KR1020190050033 A KR 1020190050033A KR 20190050033 A KR20190050033 A KR 20190050033A KR 20200126262 A KR20200126262 A KR 20200126262A
Authority
KR
South Korea
Prior art keywords
atopic dermatitis
alpha
viniferin
staphylococcus aureus
composition
Prior art date
Application number
KR1020190050033A
Other languages
Korean (ko)
Inventor
송호연
서훈희
김수경
Original Assignee
순천향대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 순천향대학교 산학협력단 filed Critical 순천향대학교 산학협력단
Priority to KR1020190050033A priority Critical patent/KR20200126262A/en
Publication of KR20200126262A publication Critical patent/KR20200126262A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9794—Liliopsida [monocotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a use of alpha-viniferin separated from Carex Humilis roots for ameliorating or treating atopic dermatitis. The alpha-viniferin capable of ameliorating atopic dermatitis is separated from Carex Humilis roots and its safety has been confirmed through a number of conventional related researches and thus its functional compound has been confirmed to provide an effect of whitening, sun protection, etc. Thus, the alpha-viniferin can be useful as a medical composition for external use or a cosmetic composition for ameliorating atopic dermatitis.

Description

황색포도상구균 특이적 억제를 통해 아토피 피부염을 개선하는 알파-비니페린 함유 아토피 피부염 개선 조성물{A composition for ameliorating atopic dermatitis through specific inhibition of Staphylococcus aureus comprising alpha-vinipherin}A composition for ameliorating atopic dermatitis through specific inhibition of Staphylococcus aureus comprising alpha-vinipherin}

본 발명은 산거울 추출물을 유효성분으로 함유하는 아토피 피부염 개선 조성물에 관한 것으로, 더욱 구체적으로 산거울 추출물(Carex humilis) 또는 이로부터 분리된 알파-비니페린(α-viniferin)을 유효성분으로 함유하는 아토피 피부염 개선효과를 갖는 피부외용 약제 조성물 또는 아토피 피부염 개선용 화장료 조성물에 관한 것이다.The present invention relates to a composition for improving atopic dermatitis containing a mountain mirror extract as an active ingredient, and more specifically, a mountain mirror extract ( Carex humilis ) or alpha-viniferin isolated therefrom as an active ingredient. It relates to an external pharmaceutical composition for skin having an atopic dermatitis improvement effect or a cosmetic composition for improving atopic dermatitis.

아토피 피부염은 주로 유아기 혹은 소아기에 시작되는 만성적이고 재발성의 염증성 피부질환으로 소양증(가려움증)과 피부건조증, 특징적인 습진을 동반한다. 아토피(atopy)는 알레르기 항원에 대한 접촉 없이 신체가 극도로 민감해지는 알레르기 반응이다. 아토피란 말은 선천적으로 과민한 알레르기 성질을 갖고 있다는 뜻이다. 여기에 '염증'이 더해진 만성 피부 질환을 통틀어 아토피성 피부염이라 부른다.Atopic dermatitis is a chronic, recurrent inflammatory skin disease that begins mainly in infancy or childhood, and is accompanied by pruritus (itch), dry skin, and characteristic eczema. Atopy is an allergic reaction in which the body becomes extremely sensitive without contact with the allergen. The word atopy means that you have an inherently sensitive allergic nature. Atopic dermatitis is called atopic dermatitis.

아토피는 정도의 차이가 있지만 어린 소아에서 발생하여 영·유아기에는 유병률이 20%에 육박하고, 학령기는 10% 전후이며, 최근 증가하고 있는 성인기 아토피피부염은 1~3%로써 전 연령에 걸쳐 영향을 미치는 질환이다(대한천식알레르기학회 보도자료 참고, 2018/04/20). 특히 어린이들에게 많이 발생해서 물리적인 고통뿐만 아니라 삶 전반에 심대한 영향을 미치는 질병이지만 현재 정확한 원인이나 치료법이 확립되어 있지 않다. 이러한 이유로 많은 환자들이 대체의학에 의존하는 경향을 보인다. 그중에서도 천연물 유래의 물질에 대한 의존도가 높다.Atopy varies in degree, but it occurs in young children, and the prevalence rate is close to 20% in infancy and infancy, around 10% in school age, and atopic dermatitis in adulthood, which is increasing recently, is 1~3%, affecting all ages. It is a disease that affects (refer to the press release of the Korean Society for Asthma and Allergy, 2018/04/20). In particular, it is a disease that occurs a lot in children and has a profound effect on not only physical pain but also overall life. For this reason, many patients tend to rely on alternative medicine. Among them, dependence on substances derived from natural products is high.

현재 기능성 화장품의 주 성분은 대부분 화학 합성 성분, 비타민, 생체 단백질등이 포함되어 매우 고가로 판매되고 있어, 같은 기능을 함유하며 저가로 원료 획득이 용이한 천연물을 이용한 원료 소재 개발이 요구되고 있는 실정이다. Currently, most of the main ingredients of functional cosmetics contain chemicalsynthetic ingredients, vitamins, and biological proteins and are sold at very high prices.Therefore, there is a need to develop raw materials using natural products that contain the same function and are easy to obtain raw materials at low cost. to be.

건강인과 아토피피부염을 환자 피부에서의 공생미생물의 분포가 다르며, 아토피 환자는 황색포도상구균(Staphylococcus aureus)이 증가하여 아토피 증상을 더욱 악화시킨다. 기존 아토피 치료방법 중에 하나인 항생제 요법의 한계는 황색포도상구균 뿐만 아니라 피부 유익균도 다 같이 억제하여 아토피 개선 효과가 뚜렷하지 않다는 것이 한계였다. 피부 공생 유익균은 억제하지 않으면서, 아토피 유발 미생물만 억제하여, 아토피 증상을 개선시키는 화장품 소재 개발이 필요한 실정이다.The distribution of symbiotic microorganisms in the skin of healthy persons and patients with atopic dermatitis is different, and Staphylococcus aureus increases in atopic patients, further exacerbating atopic symptoms. The limitation of antibiotic therapy, which is one of the existing atopic treatment methods, was that it suppressed not only Staphylococcus aureus, but also beneficial skin bacteria, so that the atopic improvement effect was not clear. There is a need to develop a cosmetic material that improves atopic symptoms by inhibiting only atopic-causing microorganisms without inhibiting skin symbiotic beneficial bacteria.

산거울(Carex humilis)은 외떡잎식물 벼목 사초과의 여러해살이풀로, 산거울 추출물이 멜란-에이(melan-a) 세포에서 티로시나제 저해 효과 및 멜라닌 생합성 저해 효과가 공지되어 있으며, 산거울 추출물 또는 이로부터 분리된 알파-비니페린의 자외선 차단가 공지되어 있다. Mountain mirror ( Carex humilis ) is a perennial plant of the monocotyledonous plant, Rice tree, Sedge family, and the mountain mirror extract has a tyrosinase inhibitory effect and melanin biosynthesis inhibitory effect in melan-a cells. UV protection of isolated alpha-viniferine is known.

그러나, 산거울 추출물 또는 이로부터 분리된 알파-비니페린의 아토피 개선효과에 대한 연구는 알려진바 없다.However, there is no known study on the atopy improvement effect of mountain mirror extract or alpha-biniferin isolated therefrom.

대한민국 등록특허 제10-1007874호Korean Patent Registration No. 10-1007874 대한민국 공개특허 제10-2008-0104759호Republic of Korea Patent Publication No. 10-2008-0104759

본 발명의 해결하고자 하는 과제는 피부자극이 없으면서도 우수한 아토피 효과를 갖는 산거울(Carex humilis) 추출물 또는 이로부터 분리된 알파-비니페린(α-viniferin)을 유효성분으로 함유하는 아토피 개선용 화장료 조성물을 제공하는 것이다.The problem to be solved of the present invention is a cosmetic composition for improving atopy that contains, as an active ingredient, a Carex humilis extract or alpha-viniferin isolated therefrom that has an excellent atopic effect without skin irritation. Is to provide.

상기의 과제를 해결하기 위해 본 발명자들은 연구노력한 결과, 산거울(Carex humilis) 추출물로부터 분리된 알파-비니페린(α-viniferin)으로 S. aureus에 대한 항균력을 평가하였고, 산거울(Carex humilis) 추출물로부터 분리된 알파-비니페린(α-viniferin)은 아토피 유발 미생물인 황색포도상구균(S. aureus)에 탁월한 성장 억제 효과를 나타냈으며 또한, 메티실린-내성 황색포도상구균(MRSA)에 대하여도 우수한 항균력을 가짐을 확인하고, 본 발명을 완성하였다.In order to solve the above problems the present inventors have sought study showed that the alpha acids isolated from the mirror (Carex humilis) Extracts were as beanie Perrin (α-viniferin) evaluate the antimicrobial activity of the S. aureus, acid mirror (Carex humilis) Alpha-viniferin isolated from the extract showed an excellent growth inhibitory effect on Staphylococcus aureus ( S. aureus ), which is atopy-causing microorganism, and also excellent against methicillin-resistant Staphylococcus aureus (MRSA). It was confirmed that it has antibacterial activity, and the present invention was completed.

상기의 과제를 해결하기 위해 본 발명은 하나의 양태로 알파-비니페린(α-viniferin)을 유효성분으로 함유하는 아토피 피부염 개선용 화장료 조성물을 제공한다.In order to solve the above problems, the present invention provides a cosmetic composition for improving atopic dermatitis containing alpha-viniferin as an active ingredient in one aspect.

본 발명의 다른 양태로 알파-비니페린(α-viniferin)을 유효성분으로 함유하는 아토피 피부염 개선용 피부외용약제 조성물을 제공한다. In another aspect of the present invention, there is provided an external skin pharmaceutical composition for improving atopic dermatitis containing alpha-viniferin as an active ingredient.

본 발명의 다른 양태로 산거울(Carex humilis)을 유효성분으로 함유하는 아토피 피부염 개선용 화장료 조성물을 제공한다. This mirror (Carex humilis) acid to another aspect of the invention provides a cosmetic composition for improving atopic dermatitis comprising as an effective ingredient.

본 발명의 또 다른 양태로 산거울(Carex humilis)을 유효성분으로 함유하는 아토피 피부염 개선 피부외용약제 조성물을 제공한다.In another aspect of the present invention, there is provided a pharmaceutical composition for external application for skin for improving atopic dermatitis, containing as an active ingredient Carex humilis .

본 발명의 산거울 추출물 및 이로부터 분리된 화합물은 다른 피부 공생 미생물들은 억제하지 않으면서 아토피 유발 미생물인 황색포도상구균(S. aureus)에 대하여 특이적으로 항균력을 나타내므로 아토피 피부염 개선을 목적으로 한 피부외용 약학조성물 및 화장료 조성물로 유용하게 이용될 수 있다.The acid mirror extract of the present invention and the compound isolated therefrom exhibit antimicrobial activity specifically against Staphylococcus aureus ( S. aureus ), a microorganism that causes atopy, without inhibiting other skin symbiotic microorganisms. It can be usefully used as a pharmaceutical composition for external skin and a cosmetic composition.

황색포도상구균(S. aureus)에 대한 항균력은 Clinical and Laboratory Standards Institute (CLSI)의 가이드라인에 따라 배지 희석법으로 측정하였다. 각 시료의 최소저지농도(minimum inhibitory concentration, MIC)는 CLSI (Clinical and Laboratory Standards Institute) (CLSI, 2012)의 지침에 따라 분석하였다. 양이온-보정 Mueller-Hinton broth가 모든 시료의 MIC를 분석하는데 사용하였다. 간단히 말하자면 96-well 플레이트의 각 웰에 200 ㎕의 시료 함유 균액(1 x 105 ~ 1 x 106 cfu/ml)을 접종하고 37 ℃에서 24 시간 동안 배양 하였다. MIC는 가시적으로 성장이 완전한 저해된 최저농도로 정의하였다. 메티실린(Methicillin)을 양성 대조군으로 사용하였다. 분석결과, 알파-비니페린(α-viniferin)은 황색포도상구균(S. aureus)에 대해 우수한 성장 억제 효과를 보였으며, 메티실린(Methicillin) 내성균주에 대해서도 우수한 성장 억제 효과를 보임을 확인하였다(표 1).Antimicrobial activity against Staphylococcus aureus ( S. aureus ) was measured by a medium dilution method according to the guidelines of the Clinical and Laboratory Standards Institute (CLSI). The minimum inhibitory concentration (MIC) of each sample was analyzed according to the guidelines of CLSI (Clinical and Laboratory Standards Institute) (CLSI, 2012). Cation-corrected Mueller-Hinton broth was used to analyze the MIC of all samples. Briefly, 200 µl of the sample-containing bacteria solution (1 x 10 5 ~ 1 x 10 6 cfu/ml) was inoculated into each well of a 96-well plate and incubated at 37° C. for 24 hours. MIC was defined as the lowest concentration at which the growth was completely inhibited. Methicillin was used as a positive control. As a result of the analysis, it was confirmed that alpha-viniferin showed excellent growth inhibitory effect against Staphylococcus aureus ( S. aureus ) and excellent growth inhibitory effect against methicillin resistant strains ( Table 1).

22종의 박테리아 균주에 대한 알파-비니페린(α-viniferin)의 MIC 측정 결과Results of MIC measurement of α-viniferin against 22 bacterial strains MicroorganismMicroorganism MIC values (μM)MIC values (μM) α-viniferinα-viniferin MethicillinMethicillin methicillin-susceptible methicillin-susceptible Staphylococcus aureusStaphylococcus aureus 9.2-18.49.2-18.4 1.15-2.31.15-2.3 methicillin-resistantmethicillin-resistant
Staphylococcus aureusStaphylococcus aureus 9.2-18.49.2-18.4 >147>147 Acinetobacter baumanniiAcinetobacter baumannii >147>147 3.9-7.83.9-7.8 Citrobacter freundiiCitrobacter freundii >147>147 >147>147 Enterobacter aerogenesEnterobacter aerogenes >147>147 >147>147 Escherichia coliEscherichia coli >147>147 >147>147 Escherichia coli O157Escherichia coli O157 >147>147 >147>147 Klebsiella pneumoniaeKlebsiella pneumoniae >147>147 >147>147 Proteus mirabilisProteus mirabilis >147>147 36.8-73.636.8-73.6 Proteus vulgarisProteus vulgaris >147>147 36.8-73.636.8-73.6 Salmonella enteritidisSalmonella enteritidis >147>147 >147>147 Salmonella paratyphi ASalmonella paratyphi A >147>147 >147>147 Salmonella typhimuriumSalmonella typhimurium >147>147 >147>147 Serratia marcescensSerratia marcescens >147>147 >147>147 Shigella boydiiShigella boydii >147>147 >147>147 Shigella flexneriShigella flexneri >147>147 >147>147 Shigella sonneiShigella sonnei >147>147 >147>147 Shigella dysenteriaeShigella dysenteriae >147>147 >147>147 Corynebacterium diphtheriaeCorynebacterium diphtheriae >147>147 1.15-2.31.15-2.3 Streptococcus pneumoniaeStreptococcus pneumoniae >147>147 1.15-2.31.15-2.3 Streptococcus pyogenesStreptococcus pyogenes >147>147 0.3-0.60.3-0.6 Streptococcus sanguisStreptococcus sanguis >147>147 0.6-1.20.6-1.2

Claims (4)

알파-비니페린(α-viniferin)을 유효성분으로 함유하는 아토피 피부염 개선용 화장료 조성물.A cosmetic composition for improving atopic dermatitis containing alpha-viniferin as an active ingredient. 알파-비니페린(α-viniferin)을 유효성분으로 함유하는 아토피 피부염 개선용 피부외용약제 조성물.A skin external pharmaceutical composition for improving atopic dermatitis containing alpha-viniferin as an active ingredient. 산거울(Carex humilis)을 유효성분으로 함유하는 아토피 피부염 개선용 화장료 조성물.A cosmetic composition for improving atopic dermatitis, containing a san mirror ( Carex humilis ) as an active ingredient. 산거울(Carex humilis)을 유효성분으로 함유하는 아토피 피부염 개선 피부외용약제 조성물.Atopic dermatitis improvement skin external pharmaceutical composition containing Sanmirol ( Carex humilis ) as an active ingredient.
KR1020190050033A 2019-04-29 2019-04-29 A composition for ameliorating atopic dermatitis through specific inhibition of Staphylococcus aureus comprising alpha-vinipherin KR20200126262A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020190050033A KR20200126262A (en) 2019-04-29 2019-04-29 A composition for ameliorating atopic dermatitis through specific inhibition of Staphylococcus aureus comprising alpha-vinipherin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020190050033A KR20200126262A (en) 2019-04-29 2019-04-29 A composition for ameliorating atopic dermatitis through specific inhibition of Staphylococcus aureus comprising alpha-vinipherin

Publications (1)

Publication Number Publication Date
KR20200126262A true KR20200126262A (en) 2020-11-06

Family

ID=73571797

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020190050033A KR20200126262A (en) 2019-04-29 2019-04-29 A composition for ameliorating atopic dermatitis through specific inhibition of Staphylococcus aureus comprising alpha-vinipherin

Country Status (1)

Country Link
KR (1) KR20200126262A (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080104759A (en) 2007-05-29 2008-12-03 주식회사 바이오랜드 Composition comprising an extract of carex humilis leyss or alpha;-viniferin compound isolated therefrom for skin whitening
KR101007874B1 (en) 2008-09-09 2011-01-14 주식회사 바이오랜드 Sunscreen Compositions comprising extracts of Carex humilis Leyss or ?-viniferins isolated therefrom

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080104759A (en) 2007-05-29 2008-12-03 주식회사 바이오랜드 Composition comprising an extract of carex humilis leyss or alpha;-viniferin compound isolated therefrom for skin whitening
KR101007874B1 (en) 2008-09-09 2011-01-14 주식회사 바이오랜드 Sunscreen Compositions comprising extracts of Carex humilis Leyss or ?-viniferins isolated therefrom

Similar Documents

Publication Publication Date Title
Voidarou et al. Antibacterial activity of different honeys against pathogenic bacteria
De Oliveira et al. Antimicrobial activity of noncytotoxic concentrations of Salvia officinalis extract against bacterial and fungal species from the oral cavity
Hasan Antibacterial activity of aqueous and alcoholic extracts of Capsella Bursa against selected pathogenic bacteria
Kwon et al. Thymol attenuates the worsening of atopic dermatitis induced by Staphylococcus aureus membrane vesicles
Keikhaie et al. Antibacterial activity of ethyl acetate and methanol extracts of Securigera securidaca, Withania sominefra, Rosmarinus officinalis and Aloe vera plants against important human pathogens
Dharmawati et al. Antibacterial activity of Lumbricus rubellus earthworm extract against Porphyromonas gingivalis as the bacterial cause of periodontitis
Goudarzi et al. Antibacterial properties of citrus limon and pineapple extracts on oral pathogenic bacteria (Streptococcus mutans and Streptococcus sanguis)
Al Bayati Antibacterial effect of ethanolic extract of Allium sativum on biofilm forming staphylococcus aureus which cause folliculitis
Rad et al. Effect of culture media on chemical stability and antibacterial activity of allicin
KR20200126262A (en) A composition for ameliorating atopic dermatitis through specific inhibition of Staphylococcus aureus comprising alpha-vinipherin
Obiang et al. Biological properties and phytochemical analysis of fractions and total extracts of cylicodiscus gabunensis harms and Morinda lucida benth
KR20190079875A (en) An anti-microbial compositions comprising Abeliophyllum distichum extract as an active ingredient
Chumpol et al. The antibacterial activity of the aqueous extract of Sida acuta Burm. F.
Shamsi et al. In-Vitro antioxidant, antibacterial and anti-inflammatory characterization of Indian honey
Poomanee et al. Ameliorative effect of Bouea macrophylla Griffth seed extract against bacteria-induced acne inflammation: in vitro study
Hamza et al. Evaluation of antibacterial activity of Sudanese bee honey against four species of bacteria
Igwo-Ezikpe et al. Phytochemical, antioxidant and antimicrobial properties of Parkia biglobosa (African Locust Bean) pods
Tavazo Zadeh et al. In vitro Antimicrobial Effect of Punica granatum Extract versus Chlorhexidine on Streptococcus sobrinus, Streptococcus sanguinis, and Candida albicans
Alotaibi et al. An in-vitro study to test antimicrobial effects of Commiphora myrrha in comparison to biocides
Khalaf et al. Inhibitory effect of Cepressus sempervirens L. and Ricinus communis L. extracts against growth of clinical Staphylococcus aureus and Pseudomonas aeruginosa isolated from cutaneous infections.
Mansur et al. Characteristics salivaricins producing streptococcus salivarius isolated from gingiva
Nayf et al. Antibacterial activity of aquatic extract of Myrtus communis leaves against periodontitis isolated bacteria
김용균 The Evaluation of Physicochemical and Biological Activities and High-Functional Antibacterial peptide produced by Bacillus strain isolated from Korean Traditional Fermented Food
Shobayo Antibacterial Activity of Pterocarpus osun L. on Multi-Drug Resistant (MDR) Escherichia coli from Wound Infections in Abeokuta, South-West Nigeria
Noviyandri et al. Effect of ethanol extract of robusta coffee leaves (Coffea canephora var. robusta) against Streptococcus mutans growth

Legal Events

Date Code Title Description
A201 Request for examination
A302 Request for accelerated examination
E902 Notification of reason for refusal
E601 Decision to refuse application